Sign up Australia
Proactive Investors - Run By Investors For Investors

WeedMD's second quarter underlines management's ability, reckons broker Haywood, which repeats 'buy'

The firm reported revenue for the three months to end June of C$2.01mln, up 83% on the previous quarter.
WeedMD's second quarter underlines management's ability, reckons broker Haywood, which repeats 'buy'
The company expects 500,000 sq ft of production space to be online by the end of this year

WeedMD Inc's (CVE:WMD) second quarter solid revenue growth showed management's ability to execute on strategy, reckons broker Haywood Securities, which has repeated a 'buy' stance and target of C$3.25.

Yesterday, the firm posted revenue for the three months to end June of C$2.01mln, which was 83% up on the previous quarter to end March.

READ: WeedMD confident about building market share as revenues soar in latest half year

Revenue of C$3.2mln for the first half represented a whopping 1,271% increase compared to the first half of fiscal 2017.

"We believe that WeedMD is well-positioned for both the medical market and adult-use market in Canada," said Haywood analyst Neal Gilmer in a note.

"With close to $40M in cash and a fully funded expansion plan, the company is on track to significantly expand production by the end of this year.

"With various provincial supply agreements in place, as well as the recently announced agreement with Shopper's Drug Mart, it is our view that the company is positioned for solid growth in 2019," he added.

That said, the broker noted the company expects 'marginal' revenue growth in the third quarter, due to a suspension of wholesale product sales and seedling sales as it ramps up production at its Strathroy greenhouse in Ontario.

READ: WeedMD Inc announces cannabis supply deal with Nova Scotia liquor corporation; shares pop

In late June initial crops were successfully moved into three grow rooms at Strathroy, or 25,000 sq ft.

Harvest of these rooms is on schedule for September this year, noted Gilmer, while the company expects a further 60,000 sq ft to be licensed and online during the fall of 2018 and the remaining 410,000 sq ft to be retrofitted and online by the end of the year.

"In addition, the company has signed supply agreements with Alberta, British Columbia, and Nova Scotia," said the analyst.

The broker noted that as with  other pot stocks it covers, it has lowered the 2018 estimates due to the timing of the adult-use legalization.

Haywood values WeedMD based on a multiple of ten times EV/EBITDA (enterprise value/ EBITDA) on its 2020 estimates, discounted by 15% to bring to one year forward basis.

WeedMD shares in Toronto are up Wednesday 6.04% to C$1.93.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full WMD profile View Profile

WeedMD Inc. Timeline

Related Articles

Laboratory testing
October 10 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use